Category

Archives

ATM/ATR

Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells

166 views | Feb 21 2022

Yadong Sun et al. thought that the combined application of ferroptosis inducers and mTOR inhibitors was a promising approach to improve therapeutic options in the treatment of bladder cancer. [Read the Full Post]

ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization

129 views | Feb 18 2022

Tingting Qin et al. found that ATRX-deficient high-grade gliomas (HGGs) displayed Chk1-mediated dysregulation of cell-cycle phase transitions. [Read the Full Post]

Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients

264 views | Dec 06 2021

María E Guerra García et al. suggest that ATM inhibitors might be particularly effective in tumors with defects in other nodes of the DNA damage response. [Read the Full Post]

MAD2B-mediated cell cycle reentry of podocytes is involved in the pathogenesis of FSGS

258 views | Dec 06 2021

Dian Bao et al. found that ATM kinase-MAD2B axis importantly contributed to the cell cycle reentry of podocytes. [Read the Full Post]

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells

231 views | Oct 27 2021

Andrea Ghelli Luserna Di Rorà et al. found that the ATR-CHK1 pathway was involved in the response to Dox-induced DNA damage. [Read the Full Post]

Ceramide modulates electrophysiological characteristics and oxidative stress of pulmonary vein cardiomyocytes

502 views | Oct 24 2021

Shih-Yu Huang et al. thought that C2 ceramide might exert the distinctive electrophysiological effect of modulating PV activities. [Read the Full Post]

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

538 views | Oct 17 2021

Beike Wang et al. revealed that mTOR activation was essential for drug resistance of melanoma to MAPK inhibitors, and provided insight into the rewiring of the signaling networks in CR melanoma. [Read the Full Post]

Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells

1021 views | Oct 17 2021

Jie Li et al. suggested that BEZ235 might reverse Doxo resistance in leukemia cells. [Read the Full Post]

Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a Phase I study

280 views | Aug 01 2021

Timothy A Yap et al. reported the safety, tolerability, maximum tolerated dose (MTD), recommended Phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile and preliminary antitumor activity of ceralasertib combined with carboplatin in patients with advanced solid tumors [Read the Full Post]

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma

285 views | Jun 03 2021

Nicolas Bertrand et al. found that Neoadjuvant vismodegib allowed for a downstaging of the surgical procedure for laBCCs in functionally sensitive locations. [Read the Full Post]